834 PENILE CANCER: PATIENT AND DISEASE CHARACTERISTICS OF 1,459 PATIENTS FROM THE VETERANS AFFAIRS CENTRAL CANCER REGISTRY (VACCR)

You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disease1 Apr 2011834 PENILE CANCER: PATIENT AND DISEASE CHARACTERISTICS OF 1,459 PATIENTS FROM THE VETERANS AFFAIRS CENTRAL CANCER REGISTRY (VACCR) Simon Y. Kimm, Rajesh Shinghal, Sandy Srinivas, and John Leppert Simon Y. KimmSimon Y. Kimm Stanford, CA More articles by this author , Rajesh ShinghalRajesh Shinghal Stanford, CA More articles by this author , Sandy SrinivasSandy Srinivas Stanford, CA More articles by this author , and John LeppertJohn Leppert Palo Alto, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.654AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Penile cancer is an uncommon malignancy, accounting for less than 1% of cancer deaths in men in the United States. Though rare, penile cancer and its treatment are associated with significant morbidity and mortality. We sought to investigate the characteristics of penile cancer cases in the Veterans Affairs Central Cancer Registry (VACCR). METHODS The VACCR is a repository for cancer data from all VA medical centers that treat cancer patients. We analyzed data from 1995 to 2008 for all penile tumors (ICDO3 sites C60.0 – C60.9). For each patient, the VACCR includes 130 fields including demographic information, tumor stage, tumor histology, treatment course, and vital status. Descriptive analysis of patient data was performed. Overall survival was calculated using Kaplan-Meier analysis. RESULTS We identified 1459 patients with penile tumors. The mean age at diagnosis was 66 years (22–97 years). Tumor histology was available in 1443 (99%) of cases. 1401 (96%) were squamous cell carcinoma; other more rare entities included basal cell carcinoma (1%), Kaposi sarcoma (1%), melanoma (1%), and benign lesions (1%). 1268 patients (87%) had staging information based on the AJCC 7th edition staging system (stage 0–47%, I–27%, II –10%, III–10%, and IV–6%). 681 patients (47%) had the histologic grade reported, with grade 1 (32%), grade 2 (42%), grade 3 (25%), and grade 4 (1%). Primary surgical therapy was performed in 1211 patients (83%). 55 patients received additional radiation therapy, and chemotherapy was administered to 91 patients (6%). The 3 year overall survival by stage was 0 (41%), I (33%), II (32%), III (8%), IV (0%). Median survival in years by stage was 2.6 (stage 0), 2.2 (stage I), 1.7 (stage II), 1.9 (stage III), and 0.6 (stage IV). Median follow-up was 1 year, with mean follow-up of 1.9 years. 951 patients (72%) had no recurrence in the follow-up period. 99 patients (7%) had recurrence of their disease, and 278 (21%) patients were never rendered disease-free. CONCLUSIONS The VACCR is a large and contemporary dataset that includes a large number of penile cancer cases. Among Veterans with penile cancer treated in the VA healthcare system, penile carcinoma is associated with poor overall survival, with survival rates worsening among patients with higher stage and higher grade tumors. Finally, despite multimodal therapy, disease eradication is a challenge. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e335-e336 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Metrics Author Information Simon Y. Kimm Stanford, CA More articles by this author Rajesh Shinghal Stanford, CA More articles by this author Sandy Srinivas Stanford, CA More articles by this author John Leppert Palo Alto, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...